TherapeuticsMD, Inc. TXMD
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
TherapeuticsMD, Inc. (TXMD) is a healthcare company listed in the US with a market value of about $22M. In the twelve months to September 30, 2026 it had revenue of $4M and net income of $122000, a net margin of 3.3%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a P/E of 187.0, 5-year revenue growth of -46% a year, a 5-year average ROIC of -22%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.
About TherapeuticsMD
TherapeuticsMD is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $15M in 2014 to $3M in 2025, a decline of about 13.6% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 24% over three years (dilution for shareholders).
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $3M | $2M | $1M | $70M | $3M | $65M | $50M | $16M | $17M | $19M |
| Net income | $122000 | -$569000 | -$2M | -$10M | $112M | -$172M | -$184M | -$176M | -$133M | -$77M | -$90M |
| Free cash flow | — | — | — | — | — | -$143M | -$160M | -$168M | -$107M | -$76M | -$70M |
| EPS (diluted) | $0.01 | $-0.05 | $-0.19 | $-0.00 | $11.96 | $-21.66 | $-0.67 | $-0.72 | $-0.59 | $-0.37 | $-0.46 |
| Net margin | 3.3% | -18.8% | -123.8% | -789.4% | 160.1% | -6700.9% | -282.9% | -354.8% | -823.7% | -458.5% | -464.3% |
| ROIC | — | -10.5% | -17.5% | -22.7% | 2.1% | -60.4% | -98.6% | -55.7% | -60.2% | -47.2% | -55.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is TherapeuticsMD’s P/E ratio?
About 187.0, based on the last twelve months of diluted earnings per share.
Is TherapeuticsMD stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does TherapeuticsMD pay a dividend?
Not currently.
Is TherapeuticsMD a good stock to buy?
We do not give buy or sell advice. TherapeuticsMD scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.